ecancer

New melanoma drug gives 63 percent reduction in risk of death compared to dacarbazine

Dr Paul Chapman, Memorial Sloan-Kettering Cancer Center

17 Jun 2011

Ipilimumab improves survival in metastatic melanoma

Prof Jedd Wolchok - Memorial Sloan-Kettering Cancer Center, New York, USA

17 Jun 2011

Highlights from 2011 and ASCO’s future

Prof George Sledge - Indiana University, USA

17 Jun 2011

ASCO 2011 highlights

Prof Gordon McVie – ecancer Managing Editor

16 Jun 2011

The future of medicine: personalised

Prof Hans Lehrach - Max Planck Institute for Molecular Genetics, Berlin, Germany

2 Jun 2011

Reducing global cancer mortality

Prof Peter Boyle - International Prevention Research Institute, Lyon, France

2 Jun 2011

The Cancer Genome Atlas (TCGA)

Dr Paul Spellman - National Cancer Institute, Bethesda, USA

21 Apr 2011

Combination therapy targeting MEK and PI3K pathways shows anti-tumour activity

Dr Johanna Bendell - Sarah Cannon Research Institute, Nashville, USA

20 Apr 2011

Ethical considerations surrounding cancer in the elderly and the pros and cons of web-based resources

Ian Banks (European Men's Health Forum), Jan Geissler (Leukamie-Online), Ellen Verschuur (Europa Donna)

17 Mar 2011

Treatment of brain metastases in melanoma patients

Dr Caroline Robert - Institute Gustave Roussy, Paris, France; Prof Alexander Eggermont - Erasmus University of Rotterdam, Netherlands

7 Feb 2011

Sarah Cannon Research Institute research developments at ASCO 2010

Dr Howard Burris, The Sarah Cannon Research Institute, Nashville

4 Feb 2011

Clinical benefits and side effects of ipilimumab in melanoma patients

Prof. Giorgio Parmiani - Fondazione San Raffaele del Monte Tabor, Milan, Italy

31 Jan 2011

More from ecancer